SRX 0.00% 17.5¢ sierra rutile holdings limited

After a very quick read all looks good IMHO.. The SARAH study...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 599 Posts.
    lightbulb Created with Sketch. 5
    After a very quick read all looks good IMHO..

    The SARAH study has been awarded an Oral Abstract at the meeting and will be presented in the General Session III on Saturday, 22nd April 2017 between 10-10:15 am local time. The Oral Abstract is entitled “SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma.”

    Details of the EASL/ILC 2017 Press Programme can be found at the following link: https://ilc-congress.eu/pressprogramme/
    Last edited by whatshername: 03/04/17
 
watchlist Created with Sketch. Add SRX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.